Pacira BioSciences Newsroom

Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock?

BarchartOct 21 21:53

Press Release: Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Dow JonesOct 21 20:00

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Fly 27% But Investors Aren't Buying For Growth

Simply Wall StOct 16 18:00

The Three-year Loss for Pacira BioSciences (NASDAQ:PCRX) Shareholders Likely Driven by Its Shrinking Earnings

Yahoo FinanceOct 5 20:03

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $15

BenzingaOct 4 23:54 · Ratings

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

Simply Wall StOct 4 23:09

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

GlobeNewswireOct 3 20:00

Executive Reshuffles: NSC, PCRX and OMI Companies in Focus

Seeking AlphaSep 29 03:54

Pacira BioSciences Appoints Lauren Riker as Interim CFO

Seeking AlphaSep 28 02:00

Express News | Pacira Biosciences Inc: Board Appointed Lauren Riker as Interim Chief Financial Officer

BreakingsSep 27 20:04

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

GlobeNewswireSep 26 20:00

Pacira BioSciences Urged to 'Aggressively' Buy Back Shares to Enhance Return

MT NewswiresSep 25 21:55

DOMA Perpetual Sends Letter To Board of Directors Of Pacira Biosciences To Immediately Accelerate And Increase Its Share Buyback Program To Enhance Return To Shareholders; Believes Pacira's Cash Balance Of $400M, Roughly 59% of Its Market...

BenzingaSep 25 20:17

Express News | Doma Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase Its Share Buyback Program to Enhance Return to Shareholders

BreakingsSep 25 20:15

Jefferies Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Cuts Target Price to $18

Jefferies analyst Glen Santangelo maintains $Pacira BioSciences(PCRX.US)$ with a buy rating, and adjusts the target price from $30 to $18.According to TipRanks data, the analyst has a success rate

Futu NewsSep 24 21:31 · Ratings

Jefferies & Co Adjusts Pacira BioSciences Price Target to $18 From $15, Maintains Buy Rating

MT NewswiresSep 24 21:13 · Ratings

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswireSep 10 04:00

Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma

Seeking AlphaSep 6 20:39 · Ratings

Lacklustre Performance Is Driving Pacira BioSciences, Inc.'s (NASDAQ:PCRX) 26% Price Drop

Simply Wall StAug 30 19:55

Pacira BioSciences Analyst Ratings

BenzingaAug 13 21:59 · Ratings